City of Hope (T Cell Manufacturing)

Duarte, CA
National Center
CAR-T Cell Therapy
200 confirmed programs · 129 sponsors · Last scored 2026-03-15
63.0
Signal Score
✓ FDA Inspections (2) ✓ Clinical Trials (200) ○ SEC Filings ○ Press

Quick Facts: City of Hope (T Cell Manufacturing)

Signal Score
63.0/100 (as of 2026-03-15)
Quality Compliance
Assessment pending
Headquarters
Duarte, CA
Modalities
CAR-T, Cell Therapy
Active CGT Programs
200 confirmed from ClinicalTrials.gov across 129 sponsors
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CGT manufacturing intelligence platform

Signal Score & Pillar Breakdown

Quality Compliance —
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA Inspections2 on record
Warning Letters0
Last InspectionNo Action Indicated (NAI) (2025-02-07)
Operations —
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs 200
Sponsors129
ModalitiesCAR-T, Cell Therapy
200 active programs across 129 sponsors
Modalities: CAR-T, Cell Therapy
121 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov facility matching
NCT07387367 A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment... PHASE3 Recruiting
NCT07219212 A Study of JNJ-90301900 in Combination With Chemoradiation... PHASE1 Recruiting
NCT04119024 Gene Modified Immune Cells After Conditioning Regimen for the... PHASE1 Recruiting
NCT04119024 Gene Modified Immune Cells After Conditioning Regimen for the... PHASE1 Recruiting
NCT06976736 A Long Term Follow-up Study of TScan TCR-T Products NA Recruiting
NCT07038447 A Study of KITE-363 in Participants With Refractory... PHASE1 Enrolling By Invitation
NCT06552416 Safety of MT-401-OTS in Patients With Relapsed AML or MDS PHASE1 Recruiting
NCT06533579 Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) PHASE1/PHASE2 Recruiting
NCT06657144 A Study of CHS-114 in Combination With Toripalimab and/or... PHASE1 Recruiting
NCT06805305 DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly... PHASE2 Recruiting
View all 200 programs →
Source: ClinicalTrials.gov · Retrieved Mar 20, 2026
Financial Stability 68.0
Parent company: City of Hope
Financial assessment: 68.0/100
Source: SEC EDGAR, press monitoring
Subsidiary of City of Hope
SEC FilingsParent: City of Hope
Parent company: City of Hope
Financial assessment: 68.0/100
Capacity 58.0
1 CGT manufacturing site: Duarte, CA
Modalities: CAR-T, Cell Therapy
Capacity assessment: 58.0/100
Sites: Duarte, CA
Source: SEC EDGAR, press monitoring, company profiles
1 CGT manufacturing site
1 CGT manufacturing site: Duarte, CA
Modalities: CAR-T, Cell Therapy
Capacity assessment: 58.0/100

FDA Inspection History

2025-02
2024-12
NAI VAI OAI
Date Site Type Observations Classification
2025-02-07 Duarte, California Human Cellular, Tissue, and Gene Therapies No No Action Indicated (NAI)
2024-12-09 Irvine, California Blood and Blood Products No No Action Indicated (NAI)
Source: FDA Data Dashboard · Retrieved Mar 20, 2026

Clinical Activity 200 studies

NCT07387367 A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus... PHASE3 Recruiting NCT07219212 A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in... PHASE1 Recruiting NCT04119024 Gene Modified Immune Cells After Conditioning Regimen for the Treatment of... PHASE1 Recruiting NCT04119024 Gene Modified Immune Cells After Conditioning Regimen for the Treatment of... PHASE1 Recruiting NCT06976736 A Long Term Follow-up Study of TScan TCR-T Products NA Recruiting NCT07038447 A Study of KITE-363 in Participants With Refractory Autoimmune Diseases PHASE1 Enrolling By Invitation NCT06552416 Safety of MT-401-OTS in Patients With Relapsed AML or MDS PHASE1 Recruiting NCT06533579 Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) PHASE1/PHASE2 Recruiting NCT06657144 A Study of CHS-114 in Combination With Toripalimab and/or Other Treatments... PHASE1 Recruiting NCT06805305 DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult... PHASE2 Recruiting NCT06528301 A Phase 1 Study of UB-VV111 With and Without Rapamycin in... PHASE1 Recruiting NCT06514794 A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in... PHASE2 Recruiting NCT06699212 A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in... PHASE3 Recruiting NCT06577025 A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With... PHASE2 Active Not Recruiting NCT05589896 A First-in-Human Study of HLA-Partially to Fully Matched Allogenic... PHASE1/PHASE2 Recruiting NCT06163534 A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head &... NA Recruiting NCT06500273 Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL PHASE2 Recruiting NCT06097832 Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis PHASE1/PHASE2 Recruiting NCT06462365 Prevention of GvHD in Participants With Hematological Malignancies... PHASE1 Recruiting NCT06391918 Phase 1 Study of GEN2 in Patients With Advanced Solid Tumors PHASE1 Terminated
+ 180 more studies
Source: ClinicalTrials.gov · Retrieved Mar 20, 2026
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
CAR-T CDMOs → Cell Therapy CDMOs →